Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 30:10:1327931.
doi: 10.3389/fmed.2023.1327931. eCollection 2023.

Management of psoriatic arthritis: a consensus opinion by expert rheumatologists

Salvatore D'Angelo  1 , Fabiola Atzeni  2 , Maurizio Benucci  3 , Gerolamo Bianchi  4 , Fabrizio Cantini  5 , Roberto Felice Caporali  6   7 , Giorgio Carlino  8 , Francesco Caso  9 , Alberto Cauli  10 , Francesco Ciccia  11 , Maria Antonietta D'Agostino  12 , Lorenzo Dagna  13   14 , Christian Dejaco  15   16 , Oscar Massimiliano Epis  17 , Maria Grazia Ferrucci  18 , Franco Franceschini  19   20 , Enrico Fusaro  21 , Marco Gabini  22 , Roberto Gerli  23 , Roberto Giacomelli  24   25 , Marcello Govoni  26 , Elisa Gremese  27 , Giuliana Guggino  28 , Annamaria Iagnocco  29 , Florenzo Iannone  30 , Bruno Laganà  31 , Ennio Lubrano  32 , Carlomaurizio Montecucco  33 , Rosario Peluso  34 , Roberta Ramonda  35 , Maurizio Rossini  36 , Carlo Salvarani  37 , Gian Domenico Sebastiani  38 , Marco Sebastiani  39 , Carlo Selmi  40   41 , Enrico Tirri  42 , Antonio Marchesoni  43   44
Affiliations

Management of psoriatic arthritis: a consensus opinion by expert rheumatologists

Salvatore D'Angelo et al. Front Med (Lausanne). .

Abstract

Background: Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease involving several articular and extra-articular structures. Despite the important progresses recently made in all of the aspects of this disease, its management is still burdened by unresolved issues. The aim of this exercise was to provide a set of statements that may be helpful for the management of PsA.

Methods: A group of 38 Italian rheumatologists with recognized expertise in PsA selected and addressed the following four topics: "early PsA," "axial-PsA," "extra-articular manifestations and comorbidities," "therapeutic goals." Relevant articles from the literature (2016-2022) were selected by the experts based on a PubMed search. A number of statements for each topic were elaborated.

Results: Ninety-four articles were selected and evaluated, 68 out of the 1,114 yielded by the literature search and 26 added by the Authors. Each of the four topic was subdivided in themes as follows: transition from psoriasis to PsA, imaging vs. CASPAR criteria in early diagnosis, early treatment for "early PsA"; axial-PsA vs. axialspondyloarthritis, diagnosis, clinical evaluation, treatment, standard radiography vs. magnetic resonance imaging for "axial PsA"; influence of inflammatory bowel disease on the therapeutic choice, cardiovascular comorbidity, bone damage, risk of infection for "comorbidities and extra-articular manifestations"; target and tools, treat-to-target strategy, role of imaging for "therapeutic goals." The final document consisted of 49 statements.

Discussion: The final product of this exercise is a set of statements concerning the main issues of PsA management offering an expert opinion for some unmet needs of this complex disease.

Keywords: chronic inflammatory musculoskeletal disease; comorbidities; consensus process; diagnosis; expert opinion; extra-articular manifestations; psoriatic arthritis; treatment.

PubMed Disclaimer

Conflict of interest statement

SD’A received consulting and speaking fees from AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Pfizer and UCB. MB had the following financing relationships with subjects with commercial interests in the health sector: BMS, Janseen, Novartis, Lilly, Abbvie, Pfizer, and Galapagos. LD received consultation honoraria from Abbvie, Amgen, Astra-Zeneca, Biogen, Boehringer-Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly and Company, Galapagos, GlaxoSmithKline, Janssen, Kiniksa Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi-Genzyme, Swedish Orphan Biovitrium (SOBI), Takeda, and Vifor Pharmaceuticals. The Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) received unrestricted research/educational grants from Abbvie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Kiniksa, Merk Sharp & Dohme, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI. CD has received consulting/speaker’s fees from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos, Sparrow and Sanofi; grant support from AbbVie and Novartis. FF received consulting/speaker fee or research support from AbbVie, Amgen, Alfa-Sigma, Biogen, Bristol-Myers Squibb, Eli-Lilly, Galapagos, Janssen, Lilly, Novartis, and Pfizer. MGa received consulting and speaking fees from Abbvie, Pfizer, Novartis, Galapagos, Janssen, MSD, Lilly, Astra Zeneca. RGe received consulting and speaking fees from AbbVie, Alfasigma, BMS, MSD, Pfizer, Roche. MGo received consulting and speaking fees from AbbVie, Amgen, Lilly, Novartis, Pfizer. EG received consulting/speaker fee or research support from AbbVie, Eli-Lilly, Galapagos, Janssen, Novartis, and Pfizer. FI received honoraria or consulting fees from Abbvie, Eli-Lilly, Galapagos, Janssen, and Pfizer. BL received speaker fee or research support from AbbVie, Eli-Lilly, Janssen, Novartis, Pfizer, and Bristol. CM received speaker’s bureau or grants from Abbvie, Amgem, BMS, Galapagos, Lilly, Novartis, and Pfizer. RR received consulting/speaker fee or research support from AbbVie, Novartis, Janssen, Eli-Lilly, Amgen, and Pfizer. MR received advisory board honoraria, consultancy fees and/or speaker fees from Abbvie, BMS, Eli-Lilly, Galapagos, Menarini, Novartis, Pfizer, Sandoz, Theramex, UCB. MS received consulting/speaker fees or research support from Bristol-Myers Squibb, Janssen, Eli-Lilly, Pfizer, Galapagos, and Boehringer-Ingheleim. CSe received consulting/speaker fee or research support from AbbVie, Amgen, Alfa-Sigma, Biogen, Eli-Lilly, EUSA-Recordati, Galapagos, Janssen, Novartis, Pfizer, SOBI. AM received consulting/speaker fee from Abbvie, Eli-Lilly, Janssen, Novartis, and UCB. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
Flowchart describing the literature selection process.
See this image and copyright information in PMC

References

    1. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. (2017) 376:957–70. doi: 10.1056/NEJMra1505557 - DOI - PubMed
    1. Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum. (2017) 47:351–60. doi: 10.1016/j.semarthrit.2017.05.010, PMID: - DOI - PubMed
    1. Tekin HG, Wu JJ, Burge R, Birt J, Egeberg A. Burden and disease characteristics of patients with psoriatic arthritis: a population-based cross-sectional study. J Rheumatol. (2019) 46:716–20. doi: 10.3899/jrheum.180670, PMID: - DOI - PubMed
    1. de Vlam K, Steinfeld S, Toukap AN, van den Bosch F, Joos R, Geysens P, et al. . The burden of psoriatic arthritis in the biologics era: data from the Belgian epidemiological psoriatic arthritis study. Rheumatology. (2021) 60:5677–85. doi: 10.1093/rheumatology/keab233, PMID: - DOI - PubMed
    1. Leung YY. Is psoriatic arthritis associated with higher risk of mortality? J Rheumatol. (2022) 49:128–31. doi: 10.3899/jrheum.210963, PMID: - DOI - PubMed